Tirzepatide vs semaglutide: how to compare Zepbound, Wegovy, Ozempic and the rest
The short answer
Tirzepatide vs semaglutide compares two molecules. Tirzepatide is sold as Zepbound and Mounjaro, and semaglutide as Wegovy, Ozempic and Rybelsus. You can fairly compare GLP-1 medicines on five points: approved uses, form, dose schedule, how you buy them, and coverage. Wegovy, Zepbound and Foundayo are approved for weight reduction, and Ozempic and Mounjaro for type 2 diabetes. Results from separate trials can't be ranked against each other.
Key takeaways
- Tirzepatide is sold as Zepbound and Mounjaro. Semaglutide is sold as Wegovy, Ozempic and Rybelsus.
- Start with approved uses. Ozempic and Mounjaro have no weight-loss approval, even though they share molecules with Wegovy and Zepbound.
- Weight results from separate trials can't be ranked. No label names one medicine as better for weight loss.
- Paying cash? Compare the dose you'll stay on, such as $349 for Wegovy 2.4 mg, not the entry price.
- The labels don't recommend using two GLP-1 medicines together. Any switch is your prescriber's decision.
Most “this drug vs that drug” articles try to name a winner. The records don’t support one. What they do support is a clear comparison on the points that decide which medicine you end up taking and what you pay for it: what each drug is approved to treat, the form it comes in, how the dose is built up, what each way of buying costs, and who covers it. This guide explains how to read those five points, why trial results from different labels can’t be stacked into a ranking, and where to find each pair compared in detail.
Every figure on our comparison pages comes from the FDA label for that drug or from our price records. The pen vs vial vs pill comparer puts the forms of any one drug side by side, by cost per fill.
Which GLP-1 medicines are there to compare?
We track eight FDA-approved brands. They contain five different molecules, and two of those molecules are sold under more than one brand.
- Tirzepatide (Eli Lilly): Zepbound and Mounjaro, both weekly injections.
- Semaglutide (Novo Nordisk): Wegovy (weekly injection and daily tablet), Ozempic (weekly injection and daily tablet) and Rybelsus (daily tablet).
- Orforglipron (Eli Lilly): Foundayo, a daily tablet.
- Dulaglutide (Eli Lilly): Trulicity, a weekly injection.
- Liraglutide (Novo Nordisk): Saxenda, a daily injection.
When two brands share a molecule, each one still has its own label, its own approved uses and its own price programs. That’s the most useful thing to understand before you compare anything else.
How do you compare GLP-1 medicines honestly?
Compare the things that are recorded the same way for every drug. There are five.
1. Approved uses
The label’s approved use (its indication) decides what a prescriber can prescribe the drug for on-label. It’s also the first thing insurers check.
- Weight reduction: Zepbound, Wegovy, Foundayo and Saxenda are approved to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. The Wegovy injection and Saxenda labels also include children aged 12 and older with obesity.
- Type 2 diabetes: Ozempic, Mounjaro, Rybelsus and Trulicity are approved to improve blood sugar control. Each also has a cardiovascular risk use in adults with type 2 diabetes, worded differently on each label, and the Ozempic injection has a kidney use.
- Other uses: Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. Wegovy is approved to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. The Wegovy injection is also approved, under accelerated approval, for noncirrhotic MASH with moderate to advanced liver fibrosis.
A drug approved for diabetes isn’t approved for weight loss just because it shares a molecule with one that is. Ozempic has no weight-loss approval, and neither does Mounjaro.
2. Form and how it is taken
The form affects your daily routine and, more than people expect, the price.
- Weekly injections: Zepbound, Mounjaro, the Wegovy pen, the Ozempic pen and Trulicity are given once weekly, at any time of day, with or without meals.
- Daily injection: Saxenda is injected once daily at any time of day.
- Daily tablets: Foundayo is taken once daily with or without food. Wegovy tablets and Rybelsus are taken in the morning on an empty stomach with up to 4 ounces of water. The Wegovy label says to wait at least 30 minutes before eating, drinking or taking other medicines by mouth.
Within one brand, the form can change the price. Zepbound’s vial and KwikPen have self-pay program prices, while its single-dose pen is the form the savings card for covered insurance applies to.
3. Dose schedule
Every one of these medicines starts low and steps up. The labels differ on how fast and how far. Zepbound and Mounjaro start at 2.5 mg and can rise in 2.5 mg steps to 15 mg. The Wegovy pen starts at 0.25 mg and the Ozempic pen at 0.25 mg, but their later steps and top doses are different. Foundayo starts at 0.8 mg and moves up in 30-day steps.
Milligrams don’t carry over from one drug to another. A dose of one medicine tells you nothing about the matching dose of another. Even two semaglutide tablets, Rybelsus and Ozempic tablets, can’t be swapped milligram for milligram, according to their shared label. Our dosing guide and the titration schedule tool show each dose ladder on its own terms.
4. Price routes
A GLP-1 medicine doesn’t have one price. It has a list price (the full price before discounts), a manufacturer self-pay price, a savings-card price for people with commercial insurance, and in some cases a Medicare Bridge copay. To compare two drugs fairly, compare the same route for both.
The lowest self-pay price at any strength is $149 a month for Foundayo, $149 for Wegovy, $299 for Zepbound, $278 for Ozempic and $499 for Mounjaro. Those are entry prices. The dose you stay on usually costs more. For example, Zepbound 15 mg vials are $449 a month when you refill on time, and the Wegovy 2.4 mg pen is $349.
Watch the conditions as closely as the amounts. Lilly’s lower prices for the higher Zepbound and Foundayo strengths depend on refilling within 45 days. Novo Nordisk’s introductory price on the lowest Wegovy and Ozempic pen doses lasts for two fills. The cost hub, the guide to paying without insurance and the cost calculator walk through each route.
5. Coverage
Coverage follows the approved use. Commercial plans often cover the diabetes medicines for people with a type 2 diabetes diagnosis and treat weight-management medicines separately, sometimes excluding them. The insurance guide explains formularies (a plan’s list of covered drugs) and prior authorization (the plan’s approval before it pays).
For Medicare, the Part D law excludes drugs “when used for anorexia, weight loss, or weight gain,” and CMS says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight loss indication. CMS lists type 2 diabetes, moderate to severe obstructive sleep apnea and noncirrhotic MASH with moderate to advanced liver fibrosis as uses that can be covered under Part D. It names Wegovy for cardiovascular risk reduction and Zepbound for sleep apnea as coverable uses. For weight management, there’s the temporary Medicare GLP-1 Bridge. It covers Wegovy, Foundayo and the Zepbound KwikPen at a $50 copay for people who qualify. The Medicare hub has the full picture.
Why can’t you line up results from separate trials?
Because the numbers came from different conditions, and the differences are big enough to change the result.
- Length. The Wegovy injection’s Study 2 measured weight at 68 weeks. The Zepbound trials and the Foundayo trials measured it after 72 weeks. The Wegovy tablet trial ran 64 weeks.
- Who was enrolled. Within a single label, results differ between people with and without type 2 diabetes. The Wegovy label says the injection “resulted in less weight reduction in patients with type 2 diabetes.” A trial that enrolled more people with diabetes will show a smaller average for that reason alone.
- Who stayed in. Some trials only randomized people who had already tolerated the drug. The Wegovy label warns that one of its trials “may not reflect the experience of patients in the general population who are first starting” for exactly this reason.
- What it was compared with. Almost every figure on these labels compares the drug with placebo (a dummy treatment) inside one trial. The gap between drug and placebo is the finding. If you lift the drug group out of one trial and set it beside the drug group of another, you throw away the comparison that made the number meaningful.
The same goes for side effects. A nausea rate from a 68-week trial in one group of people and a nausea rate from a 40-week trial in another aren’t two readings on one scale. Our comparison pages show each drug’s label table with its own trial described, and don’t rank them.
When a direct comparison does exist
Sometimes a label records a trial that tested two medicines against each other, and that’s different. The Mounjaro label includes a 40-week trial against semaglutide 1 mg in adults with type 2 diabetes taking metformin. It also includes a cardiovascular outcomes trial against dulaglutide, in which Mounjaro was non-inferior (not worse by more than a set margin) and superiority was not established. Where a record like that exists, we report it exactly as the label states it, on the pages for Mounjaro and Ozempic and Mounjaro and Trulicity. Where none exists, we make no claim about which works better.
Can you take two GLP-1 medicines together?
The labels say no. Zepbound’s says using it with other tirzepatide-containing products, or with any GLP-1 receptor agonist, isn’t recommended. Wegovy’s says the same about other semaglutide-containing products and any other GLP-1 receptor agonist. Foundayo’s says use with another GLP-1 receptor agonist isn’t recommended, and Saxenda’s has a similar limitation. A comparison is a choice between medicines, not a plan to combine them. Moving from one to another is your prescriber’s decision. Our switching guide and switching planner set out what each label says and doesn’t say.
Every comparison, pair by pair
Each page below starts with a short summary of approved uses, form, cost and coverage. Then it covers dosing, prices for both drugs, Medicare, and each label’s side-effect figures.
Brands that share a molecule
- Ozempic vs Wegovy: two semaglutide brands, one approved for type 2 diabetes and one for weight reduction.
- Mounjaro vs Zepbound: two tirzepatide brands with different approved uses and different prices.
- Ozempic vs Rybelsus: semaglutide for type 2 diabetes as a weekly pen or a daily tablet.
- Rybelsus vs Wegovy: a diabetes tablet and a weight-management brand.
Weight-management medicines
- Wegovy vs Zepbound: the two weekly injections approved for weight reduction.
- Foundayo vs Wegovy: a daily tablet and a brand that offers both a pen and a tablet.
- Foundayo vs Zepbound: Lilly’s tablet and Lilly’s injection.
- Saxenda vs Wegovy: a daily injection and a weekly one, both from Novo Nordisk.
- Saxenda vs Zepbound: daily liraglutide and weekly tirzepatide.
Type 2 diabetes medicines
- Mounjaro vs Ozempic: the pair with a head-to-head trial on the label.
- Ozempic vs Trulicity: two weekly pens for type 2 diabetes.
- Mounjaro vs Trulicity: two Lilly injections, compared in a cardiovascular outcomes trial.
- Foundayo vs Rybelsus: two daily tablets with different approved uses.
Across the two groups
- Ozempic vs Zepbound: a diabetes medicine and a weight-management medicine that people often weigh against each other.
- Mounjaro vs Wegovy: the same question from the other direction.
How to use a comparison page
Start with the approved uses, because they narrow the field before price does. If you have type 2 diabetes, start with the diabetes labels and your plan’s formulary. If your goal is weight reduction, start with the weight-management labels, and ask whether your plan covers that class of drugs at all.
Then compare the price on the route you’ll actually use: covered insurance with a savings card, self-pay, or Medicare. A drug that’s cheaper at list price can cost more on the route open to you. Last, read each drug’s side-effect table as a description of that drug in its own trials. Take questions about your own health history to your prescriber or pharmacist. These pages describe the records. They don’t choose a medicine for you.
Frequently asked questions
Semaglutide vs tirzepatide: what is the difference?
They're different molecules from different companies. Semaglutide comes from Novo Nordisk and is sold as Wegovy, Ozempic and Rybelsus. Tirzepatide comes from Eli Lilly and is sold as Zepbound and Mounjaro. Each brand has its own label. Wegovy and Zepbound are approved for weight reduction, while Ozempic, Rybelsus and Mounjaro are approved for type 2 diabetes. Milligrams don't carry over from one molecule to the other.
What is the difference between Wegovy, Zepbound and Ozempic?
They differ in molecule and in approved use. Wegovy and Ozempic both contain semaglutide, and Zepbound contains tirzepatide. Wegovy and Zepbound are approved for long-term weight reduction, and each has other uses on its label. Ozempic's approved uses are all in adults with type 2 diabetes. Each has its own doses, prices and coverage rules, which is why this site compares the three pair by pair.
Which GLP-1 is best for weight loss?
No label answers that. Wegovy, Zepbound, Foundayo and Saxenda are each approved for weight reduction, and each was tested against placebo in its own trials, with its own patients and its own length. Figures from separate trials can't be ranked against one another. What you can compare is approved use, form, dose schedule, price and coverage. Choosing a medicine is your prescriber's job.
Which GLP-1 is cheapest without insurance?
Among manufacturer self-pay prices, the lowest starting prices are $149 a month for Foundayo and $149 for Wegovy, both for the lowest tablet strength. Zepbound starts at $299 and Ozempic at $278. Starting prices aren't maintenance prices, so compare the price of the dose you expect to stay on.
Are Ozempic and Wegovy the same drug?
Both contain semaglutide and both are made by Novo Nordisk, but they're separate products with separate labels. Ozempic's label covers type 2 diabetes. Wegovy's covers weight reduction, cardiovascular risk reduction and, for the injection, MASH. Their strengths differ, and the Wegovy label says using it with other semaglutide-containing products isn't recommended.
Are Mounjaro and Zepbound the same drug?
Both contain tirzepatide and both are made by Eli Lilly, in the same six strengths. But they're separate products with separate labels. Mounjaro's approved uses are in type 2 diabetes, and Zepbound's are weight reduction and obstructive sleep apnea. Insurers treat them as different drugs, their prices differ, and the Zepbound label says not to use it with other tirzepatide-containing products.
Can you compare weight loss results between different GLP-1 trials?
Not as a ranking. The trials on each label differ in length, in who was enrolled and in how the dose was reached. The Wegovy injection's main trial ran 68 weeks, and the Zepbound and Foundayo trials ran 72 weeks. Results also differ between people with and without type 2 diabetes. Only a trial that tests two medicines against each other supports a direct comparison.
Which GLP-1 medicines come as a pill?
Four tablets are in our records. Foundayo and the Wegovy pill are approved for weight reduction, and Rybelsus and Ozempic tablets are approved for type 2 diabetes. All are taken once daily. The semaglutide tablets are taken in the morning on an empty stomach, followed by a 30-minute wait. The Foundayo label says it can be taken with or without food.
Which GLP-1 medicines does the Medicare GLP-1 Bridge cover?
The Bridge covers Wegovy (pen and tablets), Foundayo and the Zepbound KwikPen for weight management, at a $50 copay for eligible Part D enrollees. Ozempic, Mounjaro, Rybelsus, Trulicity and Saxenda aren't Bridge products. If you're prescribed a medicine for type 2 diabetes, it goes through your Part D plan instead.
Sources (34)
- 1.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 2.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 3.FDA label (DailyMed): Foundayo prescribing information, section 1
“Concomitant use with another GLP-1 receptor agonist is not recommended.”
- 4.FDA label (DailyMed): Saxenda prescribing information, section 1
“SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 5.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Administer ZEPBOUND once weekly at any time of day, with or without meals.”
- 6.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Administer MOUNJARO once weekly, any time of day, with or without meals.”
- 7.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.”
- 8.FDA label (DailyMed): Ozempic prescribing information, section 2.1
“Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.”
- 9.FDA label (DailyMed): Trulicity prescribing information, section 2.4
“Administer TRULICITY once weekly, any time of day, with or without food.”
- 10.FDA label (DailyMed): Saxenda prescribing information, section 2.1
“Inject SAXENDA subcutaneously once daily at any time of day, without regard to the timing of meals.”
- 11.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water”
- 12.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
- 13.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water”
- 14.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
- 15.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”
- 16.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“Take FOUNDAYO orally once daily, with or without food.”
- 17.FDA label (DailyMed): Zepbound prescribing information, section 14.1
“In both trials, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”
- 18.FDA label (DailyMed): Foundayo prescribing information, section 14
“In these trials, the primary efficacy parameter was mean percent change in body weight after 72 weeks of treatment.”
- 19.FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 8
“After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved 5%, 10% and 15% weight loss than those treated with placebo as shown in Table 8.”
- 20.FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 11
“After 64 weeks, treatment with WEGOVY 25 mg tablets resulted in a statistically significant reduction in body weight compared with placebo.”
- 21.FDA label (DailyMed): Wegovy prescribing information, section 8.6
“Administration of WEGOVY injection resulted in less weight reduction in patients with type 2 diabetes and obesity or overweight compared to those without type 2 diabetes and obesity or overweight”
- 22.FDA label (DailyMed): Wegovy prescribing information, section 14.2
“Because patients who discontinued WEGOVY injection during titration and those who did not reach the 2.4 mg weekly dose were not eligible for the randomized-treatment period, the results may not reflect the experience of patients in the general population who are first starting WEGOVY injection.”
- 23.FDA label (DailyMed): Mounjaro prescribing information, section 14.3, Table 5
“Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin. HbA1c (%) - Change at Week 40: Semaglutide 1 mg: -1.9; MOUNJARO 5 mg: -2.0; MOUNJARO 10 mg: -2.2; MOUNJARO 15 mg: -2.3”
- 24.FDA label (DailyMed): Mounjaro prescribing information, section 14.6
“Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established.”
- 25.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 26.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 27.CMS: Information for Part D Plans
“Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
- 28.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
Related pages
- What is Zepbound? Uses, cost, doses and side effects
- What is Wegovy? Uses, doses, pill and pen, and cost
- What is Ozempic? Uses, doses, cost and how to take it
- Mounjaro (tirzepatide): uses, cost, doses and side effects
- Foundayo (orforglipron): the once-daily weight loss pill
- GLP-1 cost: how much each medicine costs a month
